# Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

> **NCT00970502** · PHASE1,PHASE2 · COMPLETED · sponsor: **Johnny Kao** · enrollment: 15 (actual)

## Conditions studied

- Cancer of the Pharynx
- Cancer of the Larynx
- Cancer of the Neck
- Paranasal Sinus Neoplasms
- Cancer of the Head

## Interventions

- **DRUG:** erlotinib + celecoxib

## Key facts

- **NCT ID:** NCT00970502
- **Lead sponsor:** Johnny Kao
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00970502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00970502, "Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00970502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*